Crinetics Pharmaceuticals (CRNX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.00 (+1.77%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Key Insights

Critical company metrics and information
  • Share Price

    $57.76
  • Market Cap

    $5.36 Billion
  • Total Outstanding Shares

    92.74 Million Shares
  • Total Employees

    210
  • Dividend

    No dividend
  • IPO Date

    July 18, 2018
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.crinetics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$20.60 Million
Net Cash Flow From Operating Activities, Continuing$-62.82 Million
Net Cash Flow From Operating Activities$-62.82 Million
Net Cash Flow From Financing Activities, Continuing$57.33 Million
Net Cash Flow, Continuing$15.11 Million
Net Cash Flow$15.11 Million
Net Cash Flow From Financing Activities$57.33 Million
Net Cash Flow From Investing Activities, Continuing$20.60 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-76.83 Million
Preferred Stock Dividends And Other Adjustments$0.00
Depreciation and Amortization$770,000.00
Diluted Average Shares$80.09 Million
Net Income/Loss$-76.83 Million
Operating Income/Loss$-87.80 Million
Basic Average Shares$80.09 Million
Basic Earnings Per Share$-0.96
Operating Expenses$87.80 Million
Net Income/Loss Available To Common Stockholders, Basic$-76.83 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Research and Development$61.91 Million
Other Operating Expenses$25.89 Million
Costs And Expenses$87.80 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Nonoperating Income/Loss$10.97 Million
Diluted Earnings Per Share$-0.96
Income/Loss From Continuing Operations After Tax$-76.83 Million
Net Income/Loss Attributable To Parent$-76.83 Million
Benefits Costs and Expenses$0.00
Revenues$0.00

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Equity Attributable To Parent$832.98 Million
Liabilities And Equity$937.37 Million
Noncurrent Liabilities$50.83 Million
Accounts Payable$4.94 Million
Current Assets$877.59 Million
Other Current Liabilities$48.62 Million
Other Current Assets$14.89 Million
Equity$832.98 Million
Cash$862.70 Million
Equity Attributable To Noncontrolling Interest$0.00
Fixed Assets$11.71 Million
Other Non-current Assets$48.08 Million
Noncurrent Assets$59.79 Million
Liabilities$104.39 Million
Assets$937.37 Million
Current Liabilities$53.56 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.